Literature DB >> 7076780

An automated HPLC method for the assay of propranolol and its basic metabolites in plasma and urine.

M W Lo, B Silber, S Riegelman.   

Abstract

An automated HPLC method is described for the simultaneous determination of propranolol, 4-hydroxypropranolol, and N-desisopropylpropranolol in plasma and urine before and after beta-glucuronidase/aryl sulfatase treatment. It involves extraction with ether at pH 10 in the presence of ascorbic acid, added to prevent oxidation of 4-hydroxypropranolol. The compounds are then back extracted into dilute acid and assayed on an HPLC using a fluorescence detector. Three HPLC columns have been used (a phenyl, an octyl, and an octadecyl column). The last column was found to be most reproducible with minimal intercolumn variation. The solvent system includes a combination of acetonitrile, methanol, and phosphoric acid. Concentrations as low as 0.2, 1.0, and 0.2 ng/ml of propranolol, 4-hydroxypropranolol, and N-desisopropylpropranolol, respectively, can be measured using 1 ml of plasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076780     DOI: 10.1093/chromsci/20.3.126

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  10 in total

1.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

2.  Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.

Authors:  F M Williams; J E Leeser; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

3.  The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.

Authors:  M S Lennard; P R Jackson; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

4.  Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis.

Authors:  J Reichen; B Egger; N Ohara; T B Zeltner; T Zysset; A Zimmermann
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Hollow fibers as an oral sustained-release delivery system using propranolol hydrochloride.

Authors:  M A Hussain; R C DiLuccio; E Shefter; A R Hurwitz
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

7.  Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.

Authors:  R L Lalonde; R J Straka; J A Pieper; M B Bottorff; D M Mirvis
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

8.  Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.

Authors:  R L Lalonde; J A Pieper; R J Straka; M B Bottorff; D M Mirvis
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  An improved HPLC-MS/MS method for simultaneous quantification of propranolol and its two phase I metabolites in plasma of infants with hemangioma and its application to a comparative study of plasma concentrations.

Authors:  Huan He; Li Li; Libo Zhao; Ning Sun; Meng Zhang; Ying Cheng; Lu Yu; Lin Ma; Xiaoling Wang
Journal:  RSC Adv       Date:  2018-11-07       Impact factor: 4.036

10.  Quantitative analysis of propranolol hydrochloride by high performance thin layer chromatography.

Authors:  Girija Bhavar; V A Chatpalliwar
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.